Active Portfolio Companies:
- 9/1/2018 Claro Laboratories seeking an additional $0.5M raise
- 9/1/2018 Xela Founder launches company Score Pharmaceuticals
- 8/12/2018 Neoneur accepted into National I-Corps program
- 7/25/2018 Neurodel to receive SLOS foundation grant for proof of concept testing of it’s lead compounds
- 4/1/2018 Claro Laboratories announces customer sales in 2018
- 12/1/2017 Claro Laboratories closes on $1M to fund relaunch of business as part of their targeted $2 M raise
- 12/1/2017 Neoneur completes Regional I-Corps program at the University of Pennsylvania
Partner Companies:
- 6/5/2018 ARKAY – The US FDA approves RK-01 IND Application for Evaluation of first in class Beta Cell centric Drug for Type 2 Diabetes
- 4/11/2018 ARKAY Therapeutics submits IND application for RK-01
- 2/5/2018 Creatv MicroTech at 2018 Mol Med Tri-CON oral and poster presentations, exhbit and panel discussion
- 10/2/2017 ARKAY Therapeutics Announces Notice of Allowance of Patent Application for First in Class “Beta-Cell-Centric” Drug
Older Public Announcements of tTAp Participating Companies:
Aquarius acquired by Matinas BioPharma after Matinas raised approximately $20M
Aquarius Biotechnologies participated in the tTAp partnering with three potential CEOs. In the tTAp process, they were advised to focus on their lead compounds, and subsequently received an NIH grant to more their lead compound forward. They worked with one of them to develop and improve their messaging and presentation. Aquarius BioPharma’s lead compounds are now Matinas BioParmas’ lead compounds. See Aquarius in action at the tTAp
Wellesley Pharmaceuticals ~ $1M Raise
At the tTAp Wellesley revised their message and strategy to reach investors. Strengthening the delivery of their clinical potential of their compound combination, Wellesley partnered with a number of catalysts who help them connect with potential partners in Europe and the US. See Wellesley in action at the tTAp
– Endomedix receives a $1.5 M NIH Grant
– Endomedix selected as NIH featured at Bio 2015
Endomedix partnered with a catalyst with extensive experience in the hemostatic sealant market place at the tTAp. See Endomedics in action at the tTAp
– Raised $400,000 from a single investor
– LifeCuff as IRT Won NJTC Venture Fair Life Science Award
tTAp worked with IRT, or LifeCuff as it is now known, several times over the past year+. Refining their path and their needs, the tTAp advised LifeCuff on strategies to raise funds, and suggested potential avenues for growth. tTAp sponsored LifeCuff’s participation at the NJTC Venture Fair, and worked with them to prepare for the conference. See LifeCuff in action at the tTAp.
If you know of additional results, or are a tTAp company and would like to be considered for investor presentations, please contact us at results@techacceleration.us